We are inspired by the courage and determination of individuals living with complicated and often difficult-to-treat diseases. We have a portfolio of proprietary commercial products focused on alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of clinical and preclinical candidates in development for neurological disorders.
We have been at the forefront of addiction medicine for more than a decade, seeking to help people living with alcohol dependence and opioid dependence.
We are committed to addressing unmet needs in serious mental illness through the development of therapeutic options to support people living with schizophrenia and bipolar I disorder.
We are actively researching potential new treatment options for people living with narcolepsy and other sleep disorders, which impair regulation of the sleep-wake cycle and can take an immense toll on daily life.
Our mission to make innovative medicines that may help address unmet patient needs underlies our work. Our portfolio of proprietary commercial products focuses on chronic, highly prevalent conditions that represent some of the most challenging health issues of our time.
Our research and development efforts are focused on the pursuit of potential new medicines that build on our heritage in neuroscience.